Digital weight-loss services lose most of their customers, so anything that keeps people on treatment is worth real money to them. One such service in Australia added an asynchronous AI support agent and afterwards analyzed what happened across 16,556 people prescribed semaglutide [1]. The retention problem it is trying to solve is quantified in two thirds stop within a year.
The simple comparison looks like a success. Six-month adherence was 53.2% after the agent launched against 47.3% before, a difference comfortably clear of chance.
What the study identifies more confidently is what actually predicts people leaving, and the largest of those is the strangest. Intensive self-tracking during the first month, more than 25 logging events, was associated with a fifteenfold increase in the odds of dropping out. That is almost certainly not tracking causing attrition. Much more plausibly, someone logging obsessively in week two is someone already anxious about whether it is working — which makes it a warning sign worth a phone call rather than a behavior to discourage.
The number most relevant to this desk is plainer. Higher program cost was associated with roughly two and a half times the odds of attrition, alongside program pauses at a similar magnitude. Price is not merely what someone pays; it is a predictor of whether they finish, which is the argument against buying a cheap first month at a service whose maintenance pricing climbs — the pattern documented in the headline against the bill and what a twelve-month commitment locks you out of.
One definition limits everything above. Adherence here means at least six orders fulfilled within 183 days — a measure of purchasing, not of injecting. Someone who orders reliably and skips doses counts as adherent, and someone who stockpiles counts as lapsed. For a commercial service those are the data that exist, and they are a reasonable proxy, but the distinction matters when the same word is used to describe taking medicine, as in what patients said when asked.